http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2328523-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_913fa22ac7d6845e1095a7dd1446dbcf |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2250-0067 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-146 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L31-022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-91 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F2-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F2-82 |
| filingDate | 2009-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8006c88d7eaab64389dff365626a3055 |
| publicationDate | 2011-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-2328523-A2 |
| titleOfInvention | Matrix coated stent |
| abstract | The present invention relates generally to a drug eluting stent containing metallic surfaces modified in microsphere metallic matrix structure and methods for making same. More specifically, the invention relates to an expandable and implantable vascular stent having at least one matrix layer that promotes improved cellular adhesion properties for healing promotion healing and long term biocompatibility. In the case of coronary stents, the metallic matrix layer promotes re-endothelialization at sites of stent implantation, improves overall healing, and reduces inflammation and intimal disease progression. The microsphere metallic matrix layer may be optionally loaded with one or more therapeutic agent to further improve the function of the implanted stent and further augment clinical efficacy and safety. The active compounds are selected primarily for their anti-proliferative, immunosuppressive, and anti-inflammatory activities, among other properties, which prevent, in part, smooth muscle cell proliferation and promote endothelial cell growth. |
| priorityDate | 2008-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 261.